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Summary
In Chapter l, a review of the literature is presented, in which attention has
been paid to a number of aspects oÍ non-Hodgkin's lymphomas that are
relevant for the prognosis of the patient, especially in the relation to the








8) Diagnostic critera and disease staging
9) Therapy
ln an attempt to improve the therapeutic results, further investigations into
some of the above mentioned aspects have been carried out. The purposes
of the studies are outlined at the end of chapter l.
Chapters ll and ll present the studies on the significance of a careful
histocytological analysis for estimating the clinical prognosis oÍ patients with
low grade non-Hodgkin's lymphomas.
Chapter lldescribes a cytological subdivision which was made using
histologic material of 44 patients diagnosed as having a Íollicular
centroblastic/centrocytic lymphoma (FCC lymphoma), according to the Kiel
classification. The subdivision was made, taking into account the
predominating neoplastic celltype in the follicle. This resulted in the following
classification: small centrocytes with occasional centroblasts (SCC),
centrocytes with few (CBCC/A) or many centroblasts (CBCC/B)small and
large centrocytes (SLCC), and small and large centroblasts (SLCB). The
growth pattern showed marked variability between the subgroups, being
predominantly follicular in the SCC group and with a prominent component of
diffuse growth in the SLCB group. Bone marrow dissemination did not occur
in the SLCC group, whereas it was found in most cases of the other groups.
lmmunologicalfindings confirmed the B-cell type and demonstrated
monoclonality, but did no show any prognostic differences between the
various groups. Enzyme histochemicalfindings were also inconclusive in
determining differences between the groups. The cellcomposition oÍ the
neoplastic follicle seems to play a role in the behavior of FCC lymphomas and
to be directly related to other parameters as Íor instance growth and
dissemination pattern and clinical behavior.
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Chapter ll l deals with the clinical histories oÍ 30 of the patients described in
chapter l l ,  wi th a diagnosis of FCC lymphoma. lmmunological  invest igat ions
demonstrated that all lymphomas were of the B cell type, but immunopheno-
typing did not distinguish groups with difÍerent prognosis. The latter also is
valid for clinical staging, bacause patients with a stage lll or lV disease did not
behave signiÍicantly worse than did patients with a stage I or ll disease. The
histological material oÍ these patients was reclassiÍied according to the
cytological classiÍication presented in Chapter ll. The actuarial survival of the
whole group of 30 patients was 66% aÍter 5 years. The survival in the five
sybgroups, however, varied from 100% in group SCC to 0% in group SLCC.
An increased number oÍ centroblasts in the follicles was shown to representt
a signiÍicantly worse prognosis. The regonition oÍ patients with many
centroblasts at the time oÍ diagnosis makes it possible to treat this
prognostically bad group earlier with more agressive regimens in order to
reach a complete remission, similar to the treatment oÍ high-grade
lymphomas.
Chapter lV and V reflect he results and discussions of an investigation i to
new possibilities for therapeutic intervention in high-grade non-Hodgkin's
lymphomas. At the same time the reaction of the individual patient on each
cytostatic drug was looked at.
In Chapter lV the results are presented of the treatment of patients with high-
grade malignant lymphomas with a new induction schedule. This weekly
applicated regimen consists of three drugs: methylprednisolone (Solu-
Medrol), cytosine-arabinoside (Ara-C), and vincristine (Oncovin) (SOA-
regimen), administered on consecutive days. These are all drugs with short
halËlives. Treatment was given Íor two or three weeks, and apart from one
non-responder, all patients showed rapid reduction of the tumour mass.
The only side effect demonstrated was a small decrease of the blood counts,
without any apparent effect on bone marrow cellularity. In all cases, recovery
was rapid, although negatively influenced by the preceding start of
consolidation therapy. The SOA regimen resulted in rapid reduction oÍ tumour
masses with only minor side aÍÍects, thus improving the basis for conventional
cytotoxic regimens. lt requires further investigations to improve the schedule,
Íor instance by adding other drugs with phase specific actions.
Chapter V gives the results oÍ an investigation i to the possibility oÍ using
urinary polyamines as a method to study tumour cell kinetics of patients with
high-grade malignant non-Hodkin's lymphomas during treatment. Of nine
patients, treated for two to three weeks with the SOA regimen as described in
Chapter lV, all spontaneous voided urine samples were collected. Polyamines
and their metabolites were determined in each sample. In patients with small




those cases, polyamines were not suitable to measure the effect of treatment
of the tumour. Patients with large tumour masses exhibited a clear response
48 fo 72 hours after the start of treatment, consisting of increased excretions
of the polyamine degradation products spermidine, spermine and
isoputreanine. These rapid polyamine responses are important indications
concerning the attainment of a complete or partial remission, and can be
used for early evaluation of the efiect of chemotherapy. Thus, in the absence
of a response, it could be judged necessary to change treatment at an early
stage.
The curves of the polyamine metabolite concentrations plotted against time,
give insight into the tumour cell kinetics during treatment. There appeared to
be no direct relationship between tumour load and elevation of polyamine
excretion. Further investigation of the polyamine metabolism thereÍore, seems
to be important.
In conclusion, the determination oÍ polyamines in all spontaneous voided
urine samples is a non-invasive method, which gives an impression about
tumour cell kinetics during therapy.
When no polyamine response is observed 48-72 hr. after the start oÍ therapy,
an alteration in therapy has to be considered.
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